Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics and effects of Ate/Bev for over 1 year. Materials and Methods This study included patients with unresectable HCC treated with first-line Ate/Bev between May 2020 and April 2022. Those receiving Ate/Bev for 1 year or more were classified as the long-term treatment group. Results Of 246 patients, 69 (28.0%) were in the long-term treatment group, which comprised more proportions of intrahepatic tumor burden < 25%, Eastern Cooperative Oncology Group 0, and a lower proportion of portal vein tumor thrombosis than the short-term treatment group. The long-term treatment group had a higher incidence of atezolizumab-related thyroid dysfunction (31.9% vs. 10.7%, p < 0.001; median time to onset [mTTO], 2.8 months), dermatologic toxicity (29.0% vs. 14.7%, p=0.017; mTTO, 3.3 months), bevacizumab-related hypertension (44.9% vs. 22.0%, p=0.001; mTTO, 4.2 months), and proteinuria (69.6% vs. 38.4%, p < 0.001; mTTO, 6.8 months), compared to the short-term treatment group. Regarding liver function in the long-term treatment group, patients initially classified as Child-Pugh class A decreased from 87.0% to 75.4%, and albumin-bilirubin grade 1 decreased from 68.1% to 50.7% after 1 year of treatment. Conclusion The Ate/Bev long-term treatment group had a lower intrahepatic tumor burden, less portal vein tumor thrombosis, and better performance status and liver function at baseline. Atezolizumab-related immunological adverse events emerged relatively early in treatment compared to the bevacizumab-related. Additionally, some patients demonstrated liver function deterioration during long-term Ate/Bev treatment.
Abstract
Purpose Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics and effects of Ate/Bev for over 1 year. Materials and Methods This study included patients with unresectable HCC treated with first-line Ate/Bev between May 2020 and April 2022. Those receiving Ate/Bev for 1 year or more were classified as the long-term treatment group. Results Of 246 patients, 69 (28.0%) were in the long-term treatment group, which comprised more proportions of intrahepatic tumor burden < 25%, Eastern Cooperative Oncology Group 0, and a lower proportion of portal vein tumor thrombosis than the short-term treatment group. The long-term treatment group had a higher incidence of atezolizumab-related thyroid dysfunction (31.9% vs. 10.7%, p < 0.001; median time to onset [mTTO], 2.8 months), dermatologic toxicity (29.0% vs. 14.7%, p=0.017; mTTO, 3.3 months), bevacizumab-related hypertension (44.9% vs. 22.0%, p=0.001; mTTO, 4.2 months), and proteinuria (69.6% vs. 38.4%, p < 0.001; mTTO, 6.8 months), compared to the short-term treatment group. Regarding liver function in the long-term treatment group, patients initially classified as Child-Pugh class A decreased from 87.0% to 75.4%, and albumin-bilirubin grade 1 decreased from 68.1% to 50.7% after 1 year of treatment. Conclusion The Ate/Bev long-term treatment group had a lower intrahepatic tumor burden, less portal vein tumor thrombosis, and better performance status and liver function at baseline. Atezolizumab-related immunological adverse events emerged relatively early in treatment compared to the bevacizumab-related. Additionally, some patients demonstrated liver function deterioration during long-term Ate/Bev treatment.
참고문헌 (29)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
- Llovet JM, "Molecular pathogenesis and systemic therapies for hepatocellular carcinoma", Nat Cancer, 3, pp.386~401 (2022)
- Yang C, "Evolving therapeutic landscape of advanced hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 20, pp.203~222 (2023)
- Llovet JM, "Hepatocellular carcinoma : reasons for phase III failure and novel perspectives on trial design", Clin Cancer Res, 20, pp.2072~2079 (2014)
- "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.7~ (2021)
- Llovet JM, "Immunotherapies for hepatocellular carcinoma", Nat Rev Clin Oncol, 19, pp.151~172 (2022)
- Sperandio RC, "Hepatocellular carcinoma immunotherapy", Annu Rev Med, 73, pp.267~278 (2022)
- Lee MS, "Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140) : an open-label, multicentre, phase 1b study", Lancet Oncol, 21, pp.808~820 (2020)
- Lee WS, "Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity", Exp Mol Med, 52, pp.1475~1485 (2020)
- Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
- "NCCN clinical practice guidelines in oncology (NCCN Guidelines) for hepatocellular carcinoma, V.2.2023" (2023)[URL]
- Kim C, "Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma", JAMA Oncol, 8, pp.1825~1829 (2022)
- Yang H, "High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma", JHEP Rep, 5, pp.100672~ (2023)
- Zhu AX, "Alpha-fetoprotein as a potential surrogate biomarker for atezolizu-mab+bevacizumab treatment of hepatocellular carcinoma", Clin Cancer Res, 28, pp.3537~3545 (2022)
- Zhu AX, "Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma", Nat Med, 28, pp.1599~1611 (2022)
- Song YS, "Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma", Liver Cancer, 13, pp.89~98 (2024)
- An HJ, "Peripheral blood-based biomarkers for immune checkpoint inhibitors", Int J Mol Sci, 22, pp.9414~ (2021)
- Zheng Z, "Prognostic role of C-reactive protein in hepatocellular carcinoma : a systematic review and meta-analysis", Int J Med Sci, 10, pp.653~664 (2013)
- Cheon J, "Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma", Liver Int, 42, pp.674~681 (2022)
- Li DZ, "Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma : a systematic review and meta-analysis", Transl Cancer Res, 11, pp.4037~4050 (2022)
- Zhang D, "Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation : a systematic review and meta-analysis", Int J Biol Markers, 33, pp.266~274 (2018)
- Cheon J, "Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma", J Clin Oncol, 40(16 Suppl), pp.4076~ (2022)
- Kim HS, "The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma", Ther Adv Med Oncol, 14, pp.17588359221113266~ (2022)
- Yoest JM, "Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer : a short review", Immunotargets Ther, 6, pp.73~82 (2017)
- Kudo M, "Impact of bevacizumab being skipped due to adverse events of special interest for bevacizumab in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab : an exploratory analysis of the phase III IMbrave150 study", Liver Cancer, 13, pp.401~412 (2023)
- Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evid, 1, pp.EVIDoa2100070~ (2022)
- Vogel A, "79P outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremeli-mumab and durvalumab in the phase III Himalaya study", Ann Oncol, 33(Suppl 9), pp.S1463~S1464 (2022)
- Finn RS, "Results from the MORPHEUS-liver study : phase Ib", II randomized evaluation of tiragolumab(tira)in combination with atezolizumab(atezo)and bevacizumab(bev)in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma(uHCC), 2023, pp.41(16 Suppl), 4010~